BOJ Expected to Deliver December Rate Hike as Economists See Borrowing Costs Rising Through 2025 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Australia’s Labour Market Weakens as November Employment Drops Sharply 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Japan Business Sentiment Hits Four-Year High, Boosting Expectations of BOJ Rate Hike 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Russia Stocks End Flat as Energy and Retail Shares Show Mixed Performance 
Japanese beer and beverage maker Kirin is selling its China soft drinks joint venture to a Chinese investment fund, Plateau Consumer, for $994 million to enhance its pharmaceutical business.
The sale covers Kirin’s entire 40 percent stake in China Resources Kirin Beverages.
Established in 2011, China Resources Kirin Beverage had been expanding its business in China, making bottled water and bottled tea.
The move was part of its recent decision to review its investment portfolio, including foreign operations, under a management plan that runs through 2024. It comes shortly after Kirin decided to pull out of a joint venture brewery in Myanmar.
Kirin is focusing on certain areas, including pharmaceuticals and health science as well as food and beverages.
The Tokyo-based company has been streamlining its operations to focus on pharmaceutical projects like developing drugs for diseases that have no existing treatments and working on what it calls LC-Plasma to offer products that help maintain immune systems.
Kirin is among Japan’s top beer brands, and still has various global operations, including Four Roses Distillery in the U.S. and San Miguel Brewery in the Philippines.
.
